Royalty Pharma to Announce Second Quarter 2022 Financial Results on August 4, 2022

Rhea-AI Summary

Royalty Pharma (Nasdaq: RPRX) announced its second quarter 2022 financial results will be reported on August 4, 2022, before U.S. market open. A conference call and webcast will follow at 8:00 a.m. Eastern Time. Royalty Pharma is the largest biopharmaceutical royalty buyer and a leading funder of innovation in the industry. Its portfolio includes royalties from 35 commercial products, including therapies from AbbVie, Johnson & Johnson, and Biogen. The company partners with various entities to fund clinical trials and product launches.

Positive

• Royalty Pharma has a diverse portfolio with royalties on around 35 commercial products.
• Company is recognized as the largest buyer of biopharmaceutical royalties.

Negative

• None.

NEW YORK, July 14, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2022 financial results on Thursday, August 4, 2022 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day.

Conference Call Information

Please visit the “Investors” page of the company’s website at https://www.royaltypharma.com/investors/news-and-events/events to obtain conference call information and to view the live webcast. A replay of the conference call and webcast will be archived on the company's website for at least 30 days.

About Royalty Pharma

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on around 35 commercial products, including AbbVie and Johnson & Johnson’s Imbruvica, Johnson & Johnson’s Tremfya, Astellas’ and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s Trodelvy, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and 10 development-stage therapies. For more information, visit www.royaltypharma.com.

Royalty Pharma Investor Relations and Communications

+1 (212) 883-6772
ir@royaltypharma.com

FAQ

When will Royalty Pharma report Q2 2022 earnings?

Royalty Pharma will report its second quarter 2022 financial results on August 4, 2022.

What time is the Royalty Pharma Q2 2022 earnings conference call?

The conference call is scheduled for 8:00 a.m. Eastern Time on August 4, 2022.

Where can I find the Royalty Pharma Q2 earnings webcast?

The webcast can be accessed on the 'Investors' page of Royalty Pharma's website.

What is the significance of Royalty Pharma's royalty portfolio?

Royalty Pharma's portfolio includes royalties from significant therapies, ensuring continued revenue stream.

Who are some key companies in Royalty Pharma's royalty portfolio?

Key companies include AbbVie, Johnson & Johnson, and Biogen, with royalties from their major therapies.